News
Indian generics makers begin to dispatch remdesivir
Generic drugmakers Hetero and Cipla are among the first Indian manufacturers to dispatch a generic version of the investigational COVID-19 treatment remdesivir, which was originally developed by Gilead Sciences.
Generics of apixaban and chlorzoxazone approved in EU and US
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended a generic version of the anticoagulant medicine apixaban. Meanwhile in the US, the Food and Drug Administration (FDA) has approved a generic version of the muscle relaxant chlorzoxazone.
Aurobindo Pharma receives FDA approval for three generics
India-based generics maker Aurobindo Pharma (Aurobindo) has received three approvals from the US Food and Drug Administration (FDA) in recent months, including for its generic versions of guaifenesin, fluoxetine and – via partner company Eugia Pharma – methotrexate.
COVID-19 drugs: Gilead’s remdesivir and Algernon’s alternative
Gilead Sciences has signed licensing agreements with five generics manufacturers based in India and Pakistan to increase production of its experimental COVID-19 drug remdesivir.
FDA approves Proventil and Daraprim generics
The US Food and Drug Administration (FDA) has approved the first generic version of a commonly used inhaler, marketed as Proventil, and the anti-parasitic Daraprim, which has previously been the subject of a price gouging scandal.
FDA approves lung cancer and anticoagulant generics
The US Food and Drug Administration (FDA) has issued a final approval for a generic version of Alimta (pemetrexed) and two new generics of Eliquis (apixaban).
Chinese company makes copy of patented coronavirus treatment remdesivir
China’s BrightGene has successfully produced remdesivir, an experimental treatment for coronavirus, however, patents for the drug are currently held by the American company Gilead.
EMA recommends four new generics
At the Committee for Medicinal Products for Human Use’s (CHMP) January 2020 meeting, the Committee recommended four new generics, and one new biosimilar, for approval.
FDA approves generics for cancer and gout
The US Food and Drug Administration (FDA) has approved two generic versions of Novartis’ anticancer drug Afinitor (everolimus), alongside a generic of Takeda’s gout treatment Uloric (febuxostat).
FDA approves MS and prostate generics
The US Food and Drug Administration (FDA) in December 2019 approved the first generics of Gilenya (fingolimod) for multiple sclerosis (MS) and Rapaflo (silodosin) for benign prostatic hyperplasia.
Generics News Research General
- Approving generics of polymer-based parenteral...Generics/Research | Posted 26/02/2021
- AIFA updates the Transparency Lists for genericsGenerics/General | Posted 26/02/2021
- Adherence improves long-term prognosis and medi...Generics/Research | Posted 19/02/2021
- Anti-competitive strategic patenting by pharmac...Generics/Research | Posted 12/02/2021
Biosimilars News Research General
- Biosimilar approvals and launches in the USBiosimilars/General | Posted 26/02/2021
- Biosimilars approved in AustraliaBiosimilars/General | Posted 21/02/2014
- Biosimilar approvals and patent litigation in t...Biosimilars/General | Posted 19/02/2021
- Collaboration between regulatory authorities fo...Biosimilars/Research | Posted 26/02/2021